Gilead Sciences, Inc.
GILD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $29 | $27 | $27 | $27 |
| % Growth | 6% | -0.6% | -0.1% | – |
| Cost of Goods Sold | $6 | $6 | $6 | $7 |
| Gross Profit | $23 | $21 | $22 | $21 |
| % Margin | 78.3% | 76% | 79.3% | 75.8% |
| R&D Expenses | $6 | $6 | $5 | $5 |
| G&A Expenses | $3 | $3 | $5 | $5 |
| SG&A Expenses | $6 | $6 | $6 | $5 |
| Sales & Mktg Exp. | $3 | $3 | $1 | $1 |
| Other Operating Expenses | $9 | $1 | $4 | $1 |
| Operating Expenses | $21 | $13 | $14 | $11 |
| Operating Income | $2 | $8 | $7 | $10 |
| % Margin | 5.8% | 28% | 26.9% | 36.3% |
| Other Income/Exp. Net | -$1 | -$1 | -$2 | -$2 |
| Pre-Tax Income | $1 | $7 | $6 | $8 |
| Tax Expense | $0 | $1 | $1 | $2 |
| Net Income | $0 | $6 | $5 | $6 |
| % Margin | 1.7% | 20.9% | 16.8% | 22.8% |
| EPS | 0.38 | 4.54 | 3.66 | 4.96 |
| % Growth | -91.6% | 24% | -26.2% | – |
| EPS Diluted | 0.38 | 4.5 | 3.64 | 4.93 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $3 | $3 | $2 | $2 |
| EBITDA | $4 | $10 | $9 | $11 |
| % Margin | 15.4% | 38.7% | 32.4% | 41.5% |